Neurofeedback for Treatment-resistant Obsessive-compulsive Disorder (OCD)

Phase

N/A

Condition

Anxiety Disorders

Obsessive-compulsive Disorder

Panic Disorders

Treatment

N/A

Clinical Study ID

NCT03956771

OCDNF_ICVS2019

Ages 18-65
All Genders

Study Summary

The aim of this study is to teach participants with a OCD diagnosis and treatment-resistance how to decrease the response from a brain region involved in the disease by using a technique called neurofeedback. While using this technique, the participants visualize their own brain response in a screen during a MRI exam. Participants will learn strategies to decrease brain responses. The neurofeedback technique is non-invasive, without known risks to participants. With this study, it is expect that the neurofeedback training over 2 weeks (2 sessions) will reduce the OCD symptoms when compared to a control intervention based on neurofeedback's placebo effects.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Primary diagnosis of current OCD according to the fifth Diagnostic and StatisticalManual of Mental Disorders;
Treatment resistance (≥ 3 selective serotonin reuptake inhibitors in proper dose for ≥ 12 weeks).

Exclusion

Exclusion Criteria:

Concomitant psychiatric or neurological illness;
Substance abuse/dependence in the past 6 months (except nicotine/caffeine);
Acute suicidal ideation;
Psychotropic medication (except selective serotonin reuptake inhibitors, anafranil, orlow-dose hypnotic or anxiolytic taken occasionally);
MRI contraindications (pregnancy, major head trauma, severe claustrophobia, severeback pain, ferromagnetic materials/prostheses/implants inside the body, or other).

Study Design

April 05, 2019

August 31, 2021

Study Description

OCD individuals will be recruited at Hospital of Braga, Braga, Portugal, in collaboration with the Psychiatry Unit (n = 30, nonrandom convenience sample based on effect size of 0.30, alpha = beta = 0.05, and ANOVA repeated measures within-between interaction). Some participants may quit the study but sample size was predetermined considering a putative 30 percent dropout rate. Clinical history will be assessed (sociodemographic information, disease onset and severity, and previous/current treatments). The participants' neuropsychological state, the blood hormonal levels, and brain function and structure as baseline measures before and after the neurofeedback intervention will be assessed. Two MRI neurofeedback sessions will be performed during 2 weeks (2 distinct days; 36 min per session) in a 3 T MRI scanner. Data analysis will be performed with a repeated measures design (baseline and after neurofeedback) between the groups to measure brain, blood, and neuropsychological changes. Patients will be supervised by a physician to track putative complications/adverse effects during the intervention. The participation will be immediately interrupted in case of adverse reactions or symptomatic worsening and a physician will follow the participants to provide the appropriated care.

Connect with a study center

Life and Health Sciences Research Institute, School of Medicine, University of Minho
Braga, Gualtar 4710-057
Portugal
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.